Arca
Skip to content
Tools
Tools

Label Changes: Zilbrysq (zilucoplan sodium)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Zilbrysq label DailyMed has published, from Ucb, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 9
  • Sections changed, version 12 to 13: 8

What changed from version 12 to version 13

Jul 10, 2025 to Feb 5, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Warnings and precautionsChanged · punctuation or symbols only
  2. Adverse reactionsChanged · 106 words added, 106 removed
  3. Use in specific populationsChanged · 54 words added
  4. Nonclinical toxicologyChanged · 82 words added, 82 removed
  5. Patient counseling informationChanged · 33 words added
  6. Medication guideChanged · 680 words added, 616 removed
  7. Instructions for useChanged · 20 words added, 20 removed
  8. Untitled sectionChanged · 1 word added, 1 removed

Warnings and precautions

Changedpunctuation or symbols only
5 unchanged lines
Vaccination does not eliminate the risk of meningococcal infections, despite development of antibodies following vaccination.
Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of ZILBRYSQ in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated [ see Contraindications (4)] .
ZILBRYSQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) [see Warnings and Precautions (5.2)] .
20 unchanged lines

Adverse reactions

Changed106 words added, 106 removed
7 unchanged lines
A total of 212 patients were treated with ZILBRYSQ 0.3 mg/kg in clinical studies in gMG. Of these, 137 patients were exposed for at least 6 months, and 87 were exposed for at least 1 year.
In a placebo-controlled study (Study 1) in patients with gMG, 86 patients received ZILBRYSQ 0.3 mg/kg [see Clinical Studies (14)] . Of these 86 patients, approximately 61% were female, 77% were White, 8% were Asian, and 8% were of Hispanic or Latino ethnicity. The mean age at study entry was 52.6 years (range 21 to 75 years).
In a placebo-controlled study (Study 1) in patients with gMG, 86 patients received ZILBRYSQ 0.3 mg/kg [see Clinical Studies (14)] . Of these 86 patients, approximately 61% were female, 77% were White, 8% were Asian, and 8% were of Hispanic or Latino ethnicity. The mean age at study entry was 52.6 years (range 21 to 75 years). Table 2 summarizes the adverse reactions reported in at least 5% of patients treated with ZILBRYSQ and more frequently than placebo. The most common adverse reactions (reported in at least 10% of patients treated with ZILBRYSQ) were injection site reactions, upper respiratory tract infections, and diarrhea.
Table 2 summarizes the adverse reactions reported in at least 5% of patients treated with ZILBRYSQ and more frequently than placebo. The most common adverse reactions (reported in at least 10% of patients treated with ZILBRYSQ) were injection site reactions, upper respiratory tract infections, and diarrhea.
Table 2: Adverse Reactions in at least 5% of Patients Treated with ZILBRYSQ and More Frequently than in Patients who Received Placebo in Study 1
16 unchanged lines

Use in specific populations

Changed54 words added
1 unchanged line
8.1 Pregnancy
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ZILBRYSQ during pregnancy. Patients or healthcare providers may contact UCBCares at 1-844-599-CARE (2273) or email ucbcares@ucb.com, so that information about the exposure of ZILBRYSQ during pregnancy and/or breastfeeding can be collected.
Risk Summary
13 unchanged lines

Nonclinical toxicology

Changed82 words added, 82 removed
6 unchanged lines
Impairment of Fertility
Subcutaneous administration of zilucoplan (0, 1, 2, or 4 mg/kg/day) to male monkeys resulted in testicular germ cell depletion/degeneration at all doses at the end of the 13-week dosing period and after the 8-week recovery period, indicating lack of reversibility. A no-effect dose for testicular germ cell degeneration was not identified. At the lowest dose tested, plasma exposures (AUC) were similar to that in humans at the maximum recommended human dose of 32.4 mg/day.
Subcutaneous administration of zilucoplan (0, 1, 2, or 4 mg/kg/day) to male monkeys resulted in testicular germ cell depletion/degeneration at all doses at the end of the 13-week dosing period and after the 8-week recovery period, indicating lack of reversibility.
A no-effect dose for testicular germ cell degeneration was not identified. At the lowest dose tested, plasma exposures (AUC) were similar to that in humans at the maximum recommended human dose of 32.4 mg/day.

Patient counseling information

Changed33 words added
26 unchanged lines
Inform patients that pancreatitis and pancreatic cysts have been reported in patients taking ZILBRYSQ. Inform patients that persistent abdominal pain, sometimes severe or radiating to the back, which may or may not be accompanied by vomiting, is the hallmark symptom of acute pancreatitis. Instruct patients to contact their healthcare provider if these symptoms occur to determine if they should discontinue ZILBRYSQ [see Warnings and Precautions (5.4)] .
Pregnancy Registry
Advise patients that there is registry that monitors outcomes in patients with Myasthenia Gravis, including women exposed to ZILBRYSQ during pregnancy and/or breastfeeding [see Use in Specific Populations (8.1)].
Administration
4 unchanged lines

Medication guide

Changed680 words added, 616 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Issued: 21/20252026
MEDICATION GUIDE ZILBRYSQ ®(ZIL-brisk) (zilucoplan) injection, for subcutaneous use
What is the most important information I should know about ZILBRYSQ?
ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight infections.
What is the most important information I should know about ZILBRYSQ? ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight infections. ZILBRYSQ increases your chance of getting serious meningococcal infections caused by Neisseria meningitidisbacteria. Meningococcal infections may quickly become life-threatening or cause death if not recognized and treated early. You must complete or update your meningococcal vaccine(s) at least 2 weeks before your first dose of ZILBRYSQ. If you have not completed your meningococcal vaccines and ZILBRYSQ must be started right away, you should receive the required vaccine(s) as soon as possible. If you have not been vaccinated and ZILBRYSQ must be started right away, you should also receive antibiotics to take for as long as your healthcare provider tells you. If you had a meningococcal vaccine in the past, you might need additional vaccines before starting ZILBRYSQ. Your healthcare provider will decide if you need additional meningococcal vaccines. Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection:
| | fever fever with high heart rate headache and fever confusion muscle aches with flu-like symptoms | fever and a rash headache with nausea or vomiting headache with a stiff neck or stiff back eyes sensitive to light
Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection.Carry it with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.
Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection.Carry it with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly. ZILBRYSQ is only available through a program called the ZILBRYSQ Risk Evaluation and Mitigation Strategy (REMS).Before you can receive ZILBRYSQ, your healthcare provider must: enroll in the ZILBRYSQ REMS program. counsel you about the risk of meningococcal infections. give you the Patient Guide, including information about the signs and symptoms of meningococcal infection. give you a Patient Safety Cardabout your risk of meningococcal infection, as discussed above. make sure that you are vaccinated against serious infections caused by meningococcal bacteria and that you receive antibiotics if you need to start ZILBRYSQ right away and you are not up to date on your vaccines. ZILBRYSQ may also increase the risk of other types of serious infectionscaused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Certain people may be at risk of serious infections with gonorrhea. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and about regular testing. Call your healthcare provider right away if you have new signs or symptoms of infection.
ZILBRYSQ is only available through a program called the ZILBRYSQ Risk Evaluation and Mitigation Strategy (REMS).Before you can receive ZILBRYSQ, your healthcare provider must: enroll in the ZILBRYSQ REMS program. counsel you about the risk of meningococcal infections. give you the Patient Guide, including information about the signs and symptoms of meningococcal infection. give you a Patient Safety Cardabout your risk of meningococcal infection, as discussed above. make sure that you are vaccinated against serious infections caused by meningococcal bacteria and that you receive antibiotics if you need to start ZILBRYSQ right away and you are not up to date on your vaccines.
ZILBRYSQ may also increase the risk of other types of serious infectionscaused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Certain people may be at risk of serious infections with gonorrhea. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and about regular testing.
Call your healthcare provider right away if you have new signs or symptoms of infection.
What is ZILBRYSQ? ZILBRYSQ is a prescription medicine used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. It is not known if ZILBRYSQ is safe and effective in children.
Who should not use ZILBRYSQ? Do not use ZILBRYSQ if youhave a serious meningococcal infection when you are starting ZILBRYSQ treatment.
Before you use ZILBRYSQ, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever. are pregnant or plan to become pregnant. It is not known if ZILBRYSQ will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if ZILBRYSQ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use ZILBRYSQ.
Before you use ZILBRYSQ, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever. are pregnant or plan to become pregnant. It is not known if ZILBRYSQ will harm your unborn baby. There is a pregnancy registry for women who use ZILBRYSQ during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become pregnant while taking ZILBRYSQ, you or your healthcare provider can contact UCBCares at 1-844-599-CARE (2273) or email ucbcares@ucb.com, to enroll or get more information about the registry. are breastfeeding or plan to breastfeed. It is not known if ZILBRYSQ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use ZILBRYSQ. Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take and the vaccines you receive. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take and the vaccines you receive. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I use ZILBRYSQ?
How should I use ZILBRYSQ? See the detailed Instructions for Usethat comes with your ZILBRYSQ for information on how to prepare and inject a dose of ZILBRYSQ, and how to properly throw away (dispose of) used ZILBRYSQ prefilled syringes. ZILBRYSQ is given as an injection under the skin (for subcutaneous use) in a prefilled syringe. Use ZILBRYSQ exactly as prescribed by your healthcare provider. After proper training on how to prepare and inject your ZILBRYSQ syringe, you or your caregiver will inject ZILBRYSQ daily. Your healthcare provider will decide the total daily dose depending on your body weight. Each prefilled syringe is for single-use only. Throw away the prefilled syringe after each use. Do not reuse. Your daily dose of ZILBRYSQ should be injected at about the same time each day. If you miss your ZILBRYSQ dose, inject a dose as soon as possible. Then, inject your next dose at your regular scheduled time. Do not inject more than 1 dose each day. Call your healthcare provider if you are not sure what to do.
If you miss your ZILBRYSQ dose, inject a dose as soon as possible. Then, inject your next dose at your regular scheduled time. Do not inject more than 1 dose each day. Call your healthcare provider if you are not sure what to do.
What are the possible side effects of ZILBRYSQ?
What are the possible side effects of ZILBRYSQ? ZILBRYSQ may cause serious side effects, including: See " What is the most important information I should know about ZILBRYSQ?" Inflammation of the pancreas (pancreatitis) and other pancreatic problems. Pancreatitis and pancreatic cysts have happened in people who use ZILBRYSQ. Your healthcare provider will do blood tests to check your pancreas before you start treatment with ZILBRYSQ. Call your healthcare provider right awayif you have pain in your stomach area (abdomen) that will not go away. Your healthcare provider will tell you if you should stop using ZILBRYSQ. The pain may be severe or felt going from your abdomen to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis. The most common side effects of ZILBRYSQ include: injection site reactions. upper respiratory tract infections. diarrhea. Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ZILBRYSQ. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The most common side effects of ZILBRYSQ include: injection site reactions. upper respiratory tract infections. diarrhea.
Tell your healthcare provider about any side effect that bothers you or that does not go away.
These are not all the possible side effects of ZILBRYSQ.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ZILBRYSQ? ZILBRYSQ prefilled syringes may be stored in the refrigerator between 36°F to 46°F (2°C to 8°C) until the expiration date on the carton. Do not freeze ZILBRYSQ. Keep the prefilled syringes in the original carton until ready for use to protect from light. ZILBRYSQ prefilled syringes may be stored at room temperature up to 86°F (30°C) in the original carton to protect them from light for a single period of up to 3 months. Write the date you removed the prefilled syringes from the refrigerator in the space provided on the carton. After ZILBRYSQ prefilled syringes have been stored at room temperature, do not place them back in the refrigerator and throw them away if not used within the 3-month period or if the expiration date has passed, whichever occurs first. Throw away any unused portion. Keep ZILBRYSQ prefilled syringes and all medicines out of the reach of children.
Keep ZILBRYSQ prefilled syringes and all medicines out of the reach of children.
General information about the safe and effective use of ZILBRYSQ.
General information about the safe and effective use of ZILBRYSQ. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ZILBRYSQ for a condition for which it was not prescribed. Do not give ZILBRYSQ to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZILBRYSQ that is written for health professionals.
What are the ingredients in ZILBRYSQ?
Active ingredient:zilucoplan
Inactive ingredients:dibasic sodium phosphate, anhydrous, monobasic sodium phosphate, monohydrate, sodium chloride, and water for injection.
Manufactured for UCB, Inc., Smyrna, GA 30080 ZILBRYSQ ®is a registered trademark of the UCB Group of Companies. ©2024 UCB, Inc., Smyrna, GA 30080. All rights reserved. For more information, visit www.ZILBRYSQ.com or call 1-844-599-2273.
What are the ingredients in ZILBRYSQ? Active ingredient:zilucoplan Inactive ingredients:dibasic sodium phosphate, anhydrous, monobasic sodium phosphate, monohydrate, sodium chloride, and water for injection. Manufactured for UCB, Inc., Smyrna, GA 30080 ZILBRYSQ ®is a registered trademark of the UCB Group of Companies. ©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved. For more information, visit www.ZILBRYSQ.com or call 1-844-599-2273.

Instructions for use

Changed20 words added, 20 removed
34 unchanged lines
If the ZILBRYSQ prefilled syringes are stored at room temperature:
Remove 1 ZILBRYSQ prefilled syringe from the carton. Grasp the prefilled syringe body.Carefully lift the prefilled syringe straight up out of the tray ( Figures B.1 and B.2). Any remaining prefilled syringes in the carton should not be placed in the refrigerator after it has been stored at room temperature. Figure B.1 Figure B.2
| Figure B.1 | Figure B.2 |
Step 2: Inspect the ZILBRYSQ prefilled syringe
29 unchanged lines
Do nottouch the injection site again before giving your injection.
| Figure F |
Figure F
Injecting the Medicine
1 unchanged line
Hold the body of the ZILBRYSQ prefilled syringe with one hand and pull the needle cap straight off with your other hand (Figure G).
| Figure G |
Figure G
Throw away (discard) the needle cap into your household trash or a sharps disposal container.
4 unchanged lines
Use your other hand to pinch the area of cleaned skin and hold it firmly (Figure H).
| Figure H |
Figure H
Step 8: Insert the needle
2 unchanged lines
Do nottouch the needle guard activation clips.
| Figure I |
Figure I
Step 9: Release the pinched skin
When the needle is fully inserted, hold the ZILBRYSQ prefilled syringe in place and release the pinched skin (Figure J).
| Figure J |
Figure J
Do notreinsert the needle into the skin if the needle is pulled out when releasing the skin. If this happens, safely throw away (dispose of) the syringe in a sharps disposal container and get a new ZILBRYSQ prefilled syringe to give the injection.
1 unchanged line
Push the plunger head all the way down while holding onto the finger grip to inject all the medicine (Figure K).
| Figure K |
Figure K
Step 11: Release the plunger head
Slowly release the plunger head by lifting your thumb. After a complete injection, the needle guard will cover the needle and you may hear a click (Figure L).
| Figure L |
Figure L
Step 12: Throw away (dispose of) the used ZILBRYSQ prefilled syringe
22 unchanged lines

Untitled section

Changed1 word added, 1 removed
Manufactured for: UCB, Inc. 1950 Lake Park Drive Smyrna, GA 30080
ZILBRYSQ ®is a registered trademark of the UCB Group of Companies. ©20242025 UCB, Inc., Smyrna, GA 30080. All rights reserved.

Unchanged: Boxed warning, Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Description, Clinical pharmacology, Clinical studies, How supplied, PRINCIPAL DISPLAY PANEL - 16.6 mg/0.416 mL Syringe Carton Box, PRINCIPAL DISPLAY PANEL - 23 mg/0.574 mL Syringe Carton Box, PRINCIPAL DISPLAY PANEL - 32.4 mg/0.81 mL Syringe Carton Box.

Every version

9 versions of set 9f1d53d6-e495-4a3a-8bb9-680a15d25034, newest first.
VersionPublished on DailyMedCompareSPL file
13Feb 5, 2026Shown belowDownload .zip
12Jul 10, 2025With version 11Download .zip
11Mar 17, 2025With version 9Download .zip
9Sep 25, 2024With version 8Download .zip
8Jul 29, 2024With version 7Download .zip
7Jun 3, 2024With version 6Download .zip
6May 13, 2024With version 5Download .zip
5Mar 8, 2024With version 4Download .zip
4Jan 3, 2024First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.